Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Nkarta, Inc is a biotechnology business based in the US. Nkarta shares (NKTX) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$62.54 |
---|---|
52-week range | USD$22.46 - USD$79.16 |
50-day moving average | USD$46.8294 |
200-day moving average | USD$34.8205 |
Wall St. target price | USD$73.67 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.8775 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $62.54 from 2020-12-18
1 week (2021-01-07) | 12.68% |
---|---|
1 month (2020-12-17) | -7.35% |
3 months (2020-10-15) | 100.64% |
6 months (2020-07-15) | 71.11% |
1 year (2020-01-13) | N/A |
---|---|
2 years (2019-01-13) | N/A |
3 years (2018-01-13) | N/A |
5 years (2016-01-13) | N/A |
Revenue TTM | USD$385 |
---|---|
Gross profit TTM | USD$-17,101,570 |
Return on assets TTM | 0% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | USD$2.3 billion |
TTM: trailing 12 months
There are currently 1.0 million Nkarta shares held short by investors – that's known as Nkarta's "short interest". This figure is 5.3% up from 967,582 last month.
There are a few different ways that this level of interest in shorting Nkarta shares can be evaluated.
Nkarta's "short interest ratio" (SIR) is the quantity of Nkarta shares currently shorted divided by the average quantity of Nkarta shares traded daily (recently around 140552.55172414). Nkarta's SIR currently stands at 7.25. In other words for every 100,000 Nkarta shares traded daily on the market, roughly 7250 shares are currently held short.
However Nkarta's short interest can also be evaluated against the total number of Nkarta shares, or, against the total number of tradable Nkarta shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nkarta's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Nkarta shares in existence, roughly 30 shares are currently held short) or 0.034% of the tradable shares (for every 100,000 tradable Nkarta shares, roughly 34 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nkarta.
Find out more about how you can short Nkarta stock.
We're not expecting Nkarta to pay a dividend over the next 12 months.
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.